Vor Historical Financial Ratios
VOR Stock | USD 0.98 0.0007 0.07% |
Vor Biopharma is promptly reporting on over 88 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0, PTB Ratio of 0.95 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Vor Biopharma financial condition quickly.
Vor |
About Vor Financial Ratios Analysis
Vor BiopharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Vor Biopharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Vor financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Vor Biopharma history.
Vor Biopharma Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Vor Biopharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Vor Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.At this time, Vor Biopharma's Payables Turnover is relatively stable compared to the past year. As of 12/13/2024, Debt To Equity is likely to grow to 0.25, while Book Value Per Share is likely to drop 1.96.
Vor Biopharma fundamentals Correlations
Click cells to compare fundamentals
Vor Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vor Biopharma fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Ptb Ratio | 182.2 | 28.84 | 2.0 | 1.05 | 1.0 | 0.95 | |
Book Value Per Share | 0.21 | 1.3 | 5.82 | 6.34 | 2.24 | 1.96 | |
Free Cash Flow Yield | (0.007617) | (0.0291) | (0.17) | (0.36) | (0.67) | (0.64) | |
Operating Cash Flow Per Share | (0.27) | (0.98) | (1.86) | (2.15) | (1.49) | (1.57) | |
Pb Ratio | 182.2 | 28.84 | 2.0 | 1.05 | 1.0 | 0.95 | |
Free Cash Flow Per Share | (0.29) | (1.09) | (1.96) | (2.37) | (1.51) | (1.58) | |
Roic | (1.44) | (0.66) | (0.29) | (0.32) | (0.68) | (0.71) | |
Net Income Per Share | (0.31) | (1.17) | (1.85) | (2.29) | (1.75) | (1.84) | |
Payables Turnover | 0.13 | 0.59 | 2.88 | 5.06 | 4.28 | 4.5 | |
Cash Per Share | 0.17 | 1.31 | 5.58 | 5.82 | 2.04 | 2.01 | |
Pocfratio | (141.25) | (38.36) | (6.25) | (3.09) | (1.51) | (1.58) | |
Pfcf Ratio | (131.28) | (34.42) | (5.91) | (2.81) | (1.49) | (1.57) | |
Days Payables Outstanding | 2.8K | 621.32 | 126.7 | 72.19 | 85.19 | 80.93 | |
Income Quality | 0.91 | 0.84 | 1.0 | 0.92 | 0.85 | 0.69 | |
Roe | (1.5) | (0.9) | (0.32) | (0.36) | (0.78) | (0.82) | |
Ev To Operating Cash Flow | (140.59) | (37.53) | (4.78) | (2.87) | (1.55) | (1.63) | |
Pe Ratio | (121.6) | (32.13) | (6.28) | (2.9) | (1.28) | (1.35) | |
Return On Tangible Assets | (1.16) | (0.57) | (0.28) | (0.3) | (0.59) | (0.62) | |
Ev To Free Cash Flow | (130.67) | (33.67) | (4.52) | (2.61) | (1.53) | (1.61) | |
Earnings Yield | (0.008223) | (0.0311) | (0.16) | (0.35) | (0.78) | (0.74) | |
Net Debt To E B I T D A | 0.64 | 0.72 | 1.51 | 0.21 | (0.0376) | (0.0357) | |
Current Ratio | 3.45 | 4.81 | 21.12 | 18.06 | 9.04 | 7.54 | |
Tangible Book Value Per Share | 0.21 | 1.3 | 5.82 | 6.34 | 2.24 | 1.96 | |
Graham Number | 1.2 | 5.84 | 15.56 | 18.09 | 9.41 | 7.27 | |
Shareholders Equity Per Share | 0.21 | 1.3 | 5.82 | 6.34 | 2.24 | 1.96 | |
Graham Net Net | 0.12 | 0.56 | 4.87 | 4.59 | 1.34 | 1.37 | |
Interest Debt Per Share | 0.0164 | 0.49 | 0.48 | 0.98 | 0.53 | 0.46 | |
Enterprise Value Over E B I T D A | (136.21) | (32.47) | (4.89) | (2.69) | (1.36) | (1.43) | |
Price Earnings Ratio | (121.6) | (32.13) | (6.28) | (2.9) | (1.28) | (1.35) | |
Price Book Value Ratio | 182.2 | 28.84 | 2.0 | 1.05 | 1.0 | 0.95 | |
Days Of Payables Outstanding | 2.8K | 621.32 | 126.7 | 72.19 | 85.19 | 80.93 | |
Price To Operating Cash Flows Ratio | (141.25) | (38.36) | (6.25) | (3.09) | (1.51) | (1.58) | |
Price To Free Cash Flows Ratio | (131.28) | (34.42) | (5.91) | (2.81) | (1.49) | (1.57) |
Pair Trading with Vor Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Vor Stock
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.